#United States #Friendswood #Castle Biosciences #DecisionDx-Melanoma #TissueCypher

Castle Biosciences Shows Impressive Growth in Q3 2026

Castle Biosciences, Inc. (Nasdaq: CSTL) has reported remarkable performance for the third quarter of 2026, showcasing a strong financial position that reflects their commitment to innovative health solutions. With revenue hitting $102.9 million, this marks a 24% rise from the previous year’s third quarter, solidifying the firm’s position in the diagnostics market.

Derek Maetzold, the company’s President and CEO, expressed his pride in the team's consistent execution across their product portfolio. The substantial growth was bolstered by a 47% increase in the report volume of their TissueCypher® test compared to the same period last year. This increase in test volume not only indicates a rising demand for their services but also reflects the effectiveness of their ongoing marketing and operational strategies.

Key Financial Highlights

The quarterly results showed that Castle Biosciences generated $19.7 million in net cash from operating activities. This achievement demonstrates the company's diligent approach to managing expenses while still investing in strategic growth opportunities. Furthermore, the management raised their revenue guidance for the full year of 2026 to $385-395 million, up from the previous estimate of $365-375 million.

The growth was not limited to just one product. The DecisionDx®-Melanoma test continues to be foundational for the dermatology sector of Castle's offerings, showing a 5% increase in test report volume for the first nine months of 2026 compared to the same timeframe in 2025. Collectively, their dermatology commercial team managed to deliver 15,168 test reports in the third quarter alone.

Continued Commitment to Innovation

Castle's success is built on a combination of existing products and new advancements within their range. In Q3 2026, additional tests like AdvanceAD-Tx™ and DecisionDx®-SCC are diversifying the clinical services offered, enhancing the company's capacity for long-term growth. During the first nine months of 2026, total test reports for core revenue drivers (TissueCypher and DecisionDx-Melanoma) rose by 29%, further underscoring their demand.

However, challenges do exist. The DecisionDx-SCC test reports delivered fell from 4,186 in Q3 2025 to 3,882 in Q3 2026. Yet, management remains assured about their overall strategic direction, reaffirming the strength of their line-up.

Long-term Growth Perspectives

As Castle Biosciences moves forward, the goal is to maintain positive Adjusted EBITDA for not only the fourth quarter of 2026 but extending through the entirety of both 2026 and 2027. This forward-thinking approach aims at sustaining cash flow while capitalizing on upcoming market opportunities contributed by their innovative lineup of tests.

The company is also augmenting its operational capabilities through a new 55,000-square-foot laboratory and office facility located in Scottsdale, Arizona. This expansion is designed to accommodate projected growth and to further invest in developing personalized medicine solutions that can lead to better patient outcomes.

Conclusion

In summary, Castle Biosciences’ Q3 2026 results reveal a promising trajectory enhanced by innovative products and efficient operations. The proactive measures taken by leadership to provide better patient care through advanced testing solutions show their commitment to revolutionizing patient management. With an upward revision of their revenue guidance and a solid performance across various testing segments, Castle Biosciences is set to continue making significant strides in the diagnostics landscape.

The company will discuss these results in detail during its conference call scheduled for today at 4:30 p.m. ET. Investors and analysts interested in the long-term strategies of Castle should definitely tune in to gain insight into the company’s future direction.